Key result
TAVR is linked to improved NYHA and KCCQ scores across severe low-gradient aortic stenosis variants.
Why the study?
Less data is available regarding functional and quality-of-life outcomes after TAVR in patients with severe, low-gradient aortic stenosis.
Does TAVR improve NYHA class and KCCQ scores in patients with severe, low-gradient aortic stenosis?
Cohort (n=170)
No
Does TAVR improve NYHA class and KCCQ scores in patients with severe, low-gradient aortic stenosis?
TAVR provides significant functional and quality-of-life improvements at 30 days and 1 year for patients with severe, low-gradient aortic stenosis, regardless of the specific variant.
Answers are grounded in this paper and cite their sources.
May support TAVR for symptom relief in low-gradient AS; hypothesis-generating and requires RCTs before practice change.
Severe aortic stenosis is a common valvular heart disease associated with significant mortality and morbidity. Transcatheter aortic valve replacement (TAVR) is an effective treatment for this condition. Less data is available regarding functional and quality-of-life outcomes in patients with severe, low-gradient aortic stenosis following TAVR. This single-center, retrospective study compared changes in New York Heart Association (NYHA) class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at 30 days and 1 year in patients with 3 variants of severe, low-gradient aortic stenosis following TAVR. Secondary outcomes included 1-year major adverse cardiovascular event. A total of 170 patients were included. All 3 low-gradient variants had significant improvement in NYHA class and KCCQ overall scores at 30 days and 1 year. There were no significant differences in KCCQ overall scores between the 3 groups and no significant differences in secondary outcomes. Patients with low-gradient aortic stenosis experienced significant improvements in functional and quality-of-life outcomes following TAVR.
No takes yet. Share an insight, caveat, or question.
Chiang et al. (2023) conducted a cohort in severe, low-gradient aortic stenosis (n=170). Transcatheter aortic valve replacement (TAVR) vs. 3 variants of severe, low-gradient aortic stenosis was evaluated on changes in New York Heart Association (NYHA) class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at 30 days and 1 year. TAVR in patients with severe, low-gradient aortic stenosis resulted in significant improvements in NYHA class and KCCQ scores at 30 days and 1 year across all 3 variants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: